The two CAR-T therapies, Gilead Sciences Inc.’s Yescarta (axicabtagene ciloleucel) and Novartis AG’s Kymriah (tisagenlecleucel), have both been rejected for routine funding on the National Health Service in preliminary guidance from the UK's National Institute for Health and Care Excellence on cost-effectiveness grounds. But that’s not the end of the story.
NICE is impressed with the clinical performance of Yescarta and Kymriah, and has recommended them for provisional NHS coverage under...